Anti-SARS-CoV-1, Spike NTD (Clone COV1-65) – Purified No Carrier Protein

Sequenced from PBMCs from a donor who had recovered from a naturally-occurring SARS infection.

This recombinant monoclonal antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added. Due to inherent biochemical properties of antibodies, certain products may be prone to precipitation over time. Precipitation may be removed by aseptic centrifugation and/or filtration.

Liquid

Recombinant antibodies are manufactured in an animal free facility using only in vitro protein free cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates.

This antibody may be stored sterile as received at 2-8°C for up to one month. For longer term storage, aseptically aliquot in working volumes without diluting and store at ≤ -70°C. Avoid Repeated Freeze Thaw Cycles.

Research Use Only

2 – 8° C Wet Ice

COV1-65 targets the N-terminal domain (NTD) of the SARS-CoV-1 prefusion spike protein, distributed on the viral surface.

SARS-CoV-1, also known as the Severe Acute Respiratory Syndrome coronavirus, is a zoonotic virus that is believed to have originated from an animal reservoir, possibly horseshoe bats, and transmitted to humans¹. This virus primarily affects the respiratory system and can cause symptoms such as muscle pain, headache, fever, cough, dyspnea, and pneumonia^1,2. It was the first severe and readily transmissible new disease to emerge in the 21st century, with the capacity to spread globally via international air travel.

COV1-65 is a monoclonal antibody specific to the N-terminal domain (NTD) of the SARS-CoV-1 spike protein. Unlike antibodies targeting the RBD, COV1-65 does not block the ACE2 receptor but does function as a neutralizer. The NTD is important for the virus's structural integrity and function, and targeting this domain could disrupt the viral life cycle in other ways. COV1-65's binding to the NTD suggests it could be useful in inhibiting viral attachment or fusion indirectly or in combination with other neutralizing antibodies, providing a broader approach to preventing infection.

Anti-SARS-CoV-1 recognizes antigens on infected cells, including respiratory epithelial cells.

1.Mann R, Perisetti A, Gajendran M, Gandhi Z, Umapathy C, Goyal H. Clinical Characteristics, Diagnosis, and Treatment of Major Coronavirus Outbreaks. Front Med (Lausanne). 2020;7:581521.
2.Rat P, Olivier E, Dutot M. SARS-CoV-2 vs. SARS-CoV-1 management: antibiotics and inflammasome modulators potential. Eur Rev Med Pharmacol Sci. 2020;24(14):7880-7885.